Piper Sandler analyst Matt O’Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $110 to $120.
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $120
Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $110 to $120.
Related Posts
Analyst Views West Pharmaceutical’s Q4 Earnings Impressive Despite Headwinds
West Pharmaceutical Services Inc (NYSE:WST) reported Q4 2022 net sales of $708.7 million, down 3%, and organic net sales growth…
Airship AI Issues Stockholder Letter And Provides Corporate Update; Sees 2024 $11.8M Backlog Plus Pipeline Of $140M Expected To Drive Triple-Digit Revenue Growth And Positive EBITDA
2023 Nasdaq Listing Strategically Positions Company to Accelerate Growth and Revenue, and Product Launches Drive Strong Demand Across Entire Product Set Reflected in $10.9 Million Award from Department of Homeland
Why Footwear Giant Crocs Shares Are Shooting Higher Today
Footwear giant Crocs, Inc (NASDAQ: CROX) shares are trading after an updated Q4, 2023 outlook and solid preliminary 2024 guidance.